Sign In
Free Newsletter
Novartis cutting 322 more jobs at NJ headquarters (updated)
Novartis will cut 322 jobs at its East Hanover headquarters, marking the fourth round of New Jersey layoffs this year.
Novartis to acquire Myricx Bio in $1.5B cancer deal
Novartis will acquire Myricx Bio for up to $1.5B, expanding its antibody-drug conjugate pipeline for cancer treatments.
Novartis cutting more jobs at East Hanover HQ (updated)
Swiss drugmaker Novartis will eliminate 76 jobs at its East Hanover headquarters as the company continues a global restructuring effort.
Novartis reports progress on $23B US manufacturing expansion
Novartis advances its $23B U.S. manufacturing plan, expanding R&D and drug production as it aims to produce key medicines domestically.
Novartis plans 114 more job cuts at East Hanover HQ
The latest layoffs come as the company continues to restructure while investing in new domestic facilities and pipelines.
Novartis to buy Excellergy for $2B to boost allergy drugs
Novartis will acquire the California biotech, adding next-gen IgE therapy Exl-111 to its portfolio in the first half of 2026.
Novartis to acquire Synnovation’s breast cancer drug for $2B
The addition of Synnovation’s experimental treatment aims to expand Novartis' oncology portfolio as well as improve precision medicine options.
NJ sues Novartis over alleged generic drug price fixing
New Jersey joins a multistate lawsuit accusing Novartis and Sandoz of price fixing 31 generic drugs, raising costs for consumers, Medicare and Medicaid.
NJ pharma drugs among 15 targeted in Medicare price talks (updated)
CMS targets 15 high-spend drugs for Medicare price negotiations, including therapies from New Jersey-based Novartis, Johnson & Johnson and Bristol Myers Squibb.
Novartis advances $23B US manufacturing plan in Florida
The new, $70 million radioligand therapy facility is part of the company's $23 billion plan to expand domestic drug production.
NJ pharma firms join Trump drug pricing deals
Four Garden State companies are among the latest to strike agreements with the White House to lower prescription costs under the president's policy.
FDA approves Novartis’ Itvisma gene therapy for SMA
The treatment is the first of its kind for spinal muscular atrophy patients age 2 and older, offering a one-time injection option.
